Literature DB >> 17135733

Expression pattern of chemokine receptors and chemokine release in inflammatory erythroderma and Sézary syndrome.

Maria Teresa Fierro1, Alessandra Comessatti, Pietro Quaglino, Michela Ortoncelli, Simona Osella Abate, Renata Ponti, Mauro Novelli, Maria Grazia Bernengo.   

Abstract

BACKGROUND: Erythroderma can be caused by inflammatory dermatoses or cutaneous T-cell lymphoma. Even if chemokines and their receptors are involved in the skin-selective lymphocyte recruitment, their role in inflammatory erythroderma is yet unclear.
OBJECTIVE: To evaluate the chemokine release (TARC, MDC, IP-10) and to define the expression pattern of Th1- (CCR5, CXCR3) and Th2-related (CCR4) chemokine receptors in inflammatory erythroderma and Sézary syndrome (SS).
MATERIALS AND METHODS: Flow cytometry has been carried out on both circulating and skin-infiltrating T lymphocytes; serum chemokine levels have been evaluated using ELISA techniques.
RESULTS: CCR4, CCR5 and CXCR3 were expressed on about 40% of peripheral blood lymphocytes and on the majority of skin-infiltrating lymphocytes in the inflammatory erythroderma patients, whereas the leukemic CD4+CD26- subpopulation in SS was characterized by a high CCR4 expression without a concurrent increase in CCR5 or CXCR3. TARC, MDC and IP-10 serum levels were significantly increased in both erythrodermic and SS patients.
CONCLUSIONS: Our results confirm that SS is a Th2 disorder with a selective expression of CCR4, whereas inflammatory erythroderma shares an overexpression of both Th1- and Th2-related chemokine receptors, suggesting an activation of different pathways driving reactive lymphocytes to the skin. Copyright (c) 2006 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17135733     DOI: 10.1159/000096191

Source DB:  PubMed          Journal:  Dermatology        ISSN: 1018-8665            Impact factor:   5.366


  4 in total

Review 1.  Tissue-specific homing of immune cells in malignant skin tumors.

Authors:  Hajnalka Jókai; Márta Marschalkó; Judit Csomor; József Szakonyi; Orsolya Kontár; Gábor Barna; Sarolta Kárpáti; Péter Holló
Journal:  Pathol Oncol Res       Date:  2012-04-24       Impact factor: 3.201

2.  Therapeutic efficacy of CXCR3 blockade in an experimental model of severe sepsis.

Authors:  Daniela S Herzig; Yin Guo; Geping Fang; Tracy E Toliver-Kinsky; Edward R Sherwood
Journal:  Crit Care       Date:  2012-09-19       Impact factor: 9.097

3.  Cutaneous barrier leakage and gut inflammation drive skin disease in Omenn syndrome.

Authors:  Rosita Rigoni; Elena Fontana; Kerry Dobbs; Veronica Marrella; Valentina Taverniti; Virginia Maina; Amanda Facoetti; Giovanna D'Amico; Waleed Al-Herz; Mario Ernesto Cruz-Munoz; Catharina Schuetz; Andrew R Gennery; Elizabeth K Garabedian; Silvia Giliani; Deborah Draper; Ghassan Dbaibo; Raif S Geha; Isabelle Meyts; Thomas Tousseyn; Benedicte Neven; Despina Moshous; Alain Fischer; Ansgar Schulz; Andrea Finocchi; Douglas B Kuhns; Danielle L Fink; Michail S Lionakis; Muthulekha Swamydas; Simone Guglielmetti; Julie Alejo; Ian A Myles; Stefania Pittaluga; Luigi D Notarangelo; Anna Villa; Barbara Cassani
Journal:  J Allergy Clin Immunol       Date:  2020-04-18       Impact factor: 10.793

4.  Clinical diagnostic utility of IP-10 and LAM antigen levels for the diagnosis of tuberculous pleural effusions in a high burden setting.

Authors:  Keertan Dheda; Richard N Van-Zyl Smit; Leonardo A Sechi; Motasim Badri; Richard Meldau; Gregory Symons; Hoosein Khalfey; Igshaan Carr; Alice Maredza; Rodney Dawson; Helen Wainright; Andrew Whitelaw; Eric D Bateman; Alimuddin Zumla
Journal:  PLoS One       Date:  2009-03-11       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.